Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
68 hedge funds and large institutions have $489M invested in Eagle Pharmaceuticals, Inc. in 2015 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 5 closing their positions.
800% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 5
400% more funds holding in top 10
Funds holding in top 10: 1 → 5 (+4)
243% more capital invested
Capital invested by funds: $143M → $489M (+$347M)
143% more funds holding
Funds holding: 28 → 68 (+40)
63% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 8
9.64% more ownership
Funds ownership: 65.59% → 75.23% (+9.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$22.3M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$20.9M |
| 3 |
JAM
JW Asset Management
Miami Beach,
Florida
|
+$18M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$8.98M |
| 5 |
Morgan Stanley
New York
|
+$5.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$10.7M |
| 2 |
GE
General Electric
Evendale,
Ohio
|
-$6.06M |
| 3 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$4.97M |
| 4 |
DM
Deerfield Management
New York
|
-$4.41M |
| 5 |
TAM
THB Asset Management
Norwalk,
Connecticut
|
-$4.38M |
EGRX Hedge Fund Activity: Q1 2015 in Review
68 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q1 2015, worth a combined $489M — up 243% from $143M a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new EGRX positions and 5 closed out — a net gain of 40 holders — while 13 added to existing stakes and 8 trimmed.
The largest buyer was Janus Henderson Investors US, opening a new position worth an estimated $22.3M. The largest seller was Jennison Associates, exiting entirely with an estimated $10.7M sold.
- 68 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q1 2015, up from 28 in Q4 2014.
- Funds reported $489M of Eagle Pharmaceuticals, Inc. stock for Q1 2015, up 243% quarter-over-quarter.
- 45 funds opened new Eagle Pharmaceuticals, Inc. positions in Q1 2015 and 5 closed out, a net change of +40 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q1 2015 was Janus Henderson Investors US, an estimated $22.3M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q1 2015 was Jennison Associates, an estimated $10.7M sold.
Based on aggregated 13F filings for Q1 2015.